otub2

OTUB2-IN-1 is a selective OTUB2 inhibitor with anti-tumor activity that inhibits the expression of PD-L1 protein in tumor cells and inhibits tumor growth, and can be used to study skin cancer and non-small cell lung cancer (NSCLC).

Huib32 is a potent small-molecule USP32 inhibitor with an IC₅₀ of 21.2 nM and high selectivity over closely related deubiquitinases (DUBs) including USP8/10/16, UCHL1, and OTUB2. It inhibits USP32 via reversible covalent binding to the active site Cys743, thereby increasing substrate ubiquitination, altering endosomal morphology, and producing biological phenotypes similar to USP32 knockout. It can be used in research on breast cancer, ovarian cancer, lung cancer, Alzheimer’s disease, Parkinson’s disease, and other diseases.

LN5P45, an OTUB2 inhibitor (IC50: 2.3 μM), promotes monoubiquitination of OTUB2 at lysine 31 and is utilized in the study of tumor progression and metastasis [1].